Inhibition of GSK-3β activity can result in drug and hormonal resistance and alter sensitivity to targeted therapy in MCF-7 breast cancer cells
出版年份 2014 全文链接
标题
Inhibition of GSK-3β activity can result in drug and hormonal resistance and alter sensitivity to targeted therapy in MCF-7 breast cancer cells
作者
关键词
-
出版物
CELL CYCLE
Volume 13, Issue 5, Pages 820-833
出版商
Informa UK Limited
发表日期
2014-02-06
DOI
10.4161/cc.27728
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging
- (2016) Linda S. Steelman et al. Aging-US
- Will PI3K pathway inhibitors be effective as single agents in patients with cancer?
- (2015) Joan T. Garrett et al. Oncotarget
- MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk
- (2015) Stian Knappskog et al. Oncotarget
- Unraveling the complexity of basal-like breast cancer
- (2015) Oncotarget
- Elevated PI3K signaling drives multiple Breast Cancer subtypes
- (2015) Jessica Adams et al. Oncotarget
- Network Modeling of MDM2 Inhibitor-Oxaliplatin Combination Reveals Biological Synergy in wt-p53 solid tumors
- (2015) Asfar S. Azmi et al. Oncotarget
- Involvement of Akt-1 and mTOR in Sensitivity of Breast Cancer to Targeted Therapy
- (2015) Melissa L. Sokolosky et al. Oncotarget
- Cooperative Effects of Akt-1 and Raf-1 on the Induction of Cellular Senescence in Doxorubicin or Tamoxifen Treated Breast Cancer Cells
- (2015) Jackson R. Taylor et al. Oncotarget
- Phosphorylation of AKT: a Mutational Analysis.
- (2015) Jonathan R. Hart et al. Oncotarget
- Epigenetic control of an oncogenic microRNA, miR-155, by BRCA1
- (2015) Oncotarget
- BRCA1/p220 loss triggers BRCA1-IRIS overexpression via mRNA stabilization in breast cancer cells
- (2015) Yoshiko Shimizu et al. Oncotarget
- Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades
- (2015) James Andrew McCubrey et al. Oncotarget
- Effects of Ectopic Expression of NGAL on Doxorubicin Sensitivity.
- (2015) William H Chappell et al. Oncotarget
- Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance
- (2015) James Andrew McCubrey et al. Oncotarget
- Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention
- (2013) J A McCubrey et al. LEUKEMIA
- Glycogen synthase kinase-3β positively regulates protein synthesis and cell proliferation through the regulation of translation initiation factor 4E-binding protein 1
- (2013) S Shin et al. ONCOGENE
- GSK-3 inhibition in vitro and in vivo enhances antitumor effect of sorafenib in renal cell carcinoma (RCC)
- (2012) Hisashi Kawazoe et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Glycogen synthase kinase (GSK)-3 and mammalian target of rapamycin complex 1 (mTORC1) cooperate to regulate protein S6 kinase 1 (S6K1)
- (2012) Sejeong Shin et al. CELL CYCLE
- Mesenchymal traits are selected along with stem features in breast cancer cells grown as mammospheres
- (2012) Silvia Borgna et al. CELL CYCLE
- Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine
- (2012) William H. Chappell et al. CELL CYCLE
- The specific role of pRb in p16INK4A-mediated arrest of normal and malignant human breast cells
- (2012) Alexey V. Bazarov et al. CELL CYCLE
- BRCA1 mutations drive oxidative stress and glycolysis in the tumor microenvironment
- (2012) Ubaldo E. Martinez-Outschoorn et al. CELL CYCLE
- New light on p27kip1 in breast cancer
- (2012) Barbara Belletti et al. CELL CYCLE
- The role of S6K1 in ER-positive breast cancer
- (2012) Marina K. Holz CELL CYCLE
- ShRNA silencing glycogen synthase kinase-3 beta inhibits tumor growth and angiogenesis in pancreatic cancer
- (2011) Wei Zhou et al. CANCER LETTERS
- RB pathway and therapeutic sensitivity: New insights in breast cancer and Tamoxifen therapy
- (2011) Agnieszka K. Witkiewicz et al. CELL CYCLE
- RB1 and p53 at the crossroad of EMT and triple-negative breast cancer
- (2011) Zhe Jiang et al. CELL CYCLE
- RareBRCA1haplotypes including 3’UTR SNPs associated with breast cancer risk
- (2011) Cory Pelletier et al. CELL CYCLE
- BRCA1, microRNAs and cancer predisposition: Challenging the dogma
- (2011) Maria Inês Almeida et al. CELL CYCLE
- A non-functional retinoblastoma tumor suppressor (RB) pathway in premenopausal breast cancer is associated with resistance to tamoxifen
- (2011) Sophie Lehn et al. CELL CYCLE
- Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells
- (2011) Linda S. Steelman et al. CELL CYCLE
- Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs
- (2011) Rosa Puca et al. CELL CYCLE
- Anticancer efficacy of deguelin in human prostate cancer cells targeting glycogen synthase kinase-3 β/β-catenin pathway
- (2011) Vijayalakshmi Thamilselvan et al. INTERNATIONAL JOURNAL OF CANCER
- Overexpression of Glycogen Synthase Kinase-3 in Ovarian Carcinoma Cells With Acquired Paclitaxel Resistance
- (2011) Yunfeng Fu et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Convergence of the Mammalian Target of Rapamycin Complex 1- and Glycogen Synthase Kinase 3- -Signaling Pathways Regulates the Innate Inflammatory Response
- (2011) H. Wang et al. JOURNAL OF IMMUNOLOGY
- Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway
- (2011) A M Martelli et al. LEUKEMIA
- Glycogen synthase kinase (GSK)-3 promotes p70 ribosomal protein S6 kinase (p70S6K) activity and cell proliferation
- (2011) S. Shin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Expression analysis of E-cadherin, Slug and GSK3β in invasive ductal carcinoma of breast
- (2009) Chandra P Prasad et al. BMC CANCER
- Glycogen synthase kinase 3β (GSK3β) in tumorigenesis and cancer chemotherapy
- (2008) Jia Luo CANCER LETTERS
- Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors
- (2008) L S Steelman et al. ONCOGENE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started